Science Translational Medicine (journal)

Resistance to COVID-19 drug detected in lab study

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

Research by Dane Chetkovich, MD, PhD, right, Ye Han, PhD, and colleagues on how antidepressants work points to possible new targets for drug development.

Study provides new insight into how antidepressant drugs work

A study by Vanderbilt researchers sheds light on how current antidepressant drugs work and suggests a new drug target in depression.

VUMC team aids development of potential antiviral drug for COVID-19

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Triple-negative breast cancer drug therapy shows promise

Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

Potential second-line melanoma treatment identified

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

New target for chronic kidney disease

Preventing the formation of secretory structures that promote scarring in the kidney could offer new therapeutic options for a disease that affects millions of people worldwide.

1 2